About Careers MedBlog Contact us

High Out of Pocket Cost of Medications to Treat Cardiovascular Diseases in India

by Madhumathi Palaniappan on May 14, 2016 at 6:15 PM
Font : A-A+

High Out of Pocket Cost of Medications to Treat Cardiovascular Diseases in India

In India, people continue to have high financial burden on essential medicines to treat cardiovascular diseases.

Large portion of health expenses in many middle and low income countries is mainly due to high cost of medicines. According to a study by the University of Chicago, the financial burden is mainly due to the expenses on medicines used for the treatment of cardiovascular ailments like hypertension, hyperlipidemia (increased cholesterol levels), and coronary heart diseases in India.


Although medicines serve as an essential life savior in the treatment of various diseases, they seem to be responsible for causing significant financial burden to millions of people in India making them even more economically weak. 

According to the data collected by the National Sample survey (NSS) in the year 2011-2012. Cardiovascular medications benefit as many as 170 million Indian people taking into account both the rural as well as the urban adult population. Out of which around 45 million people in rural areas and 30 million in urban areas are finding it difficult to afford for medicines.

High out of pocket cost on cardiovascular medicines could push as many as 17 million rural people and 10 million urban Indians below poverty line. This number increases the poverty line by 3.2% in the cities and about 2% in rural areas. If majority of 75% of the 170 million people tend to buy medicines out of their pocket it would definitely affect  and make medicines unaffordable for 13 million people in the rural areas and 7 million in the cities resulting in impoverishment.

The study was based on the findings on Financial Burden and Impoverishment due to Cardiovascular Medications in Low and Middle Income Countries: an Illustration from India and was done by Professor Kiran Pandey and Professor David Meltzer from University of Chicago.

Source: Medindia


Recommended Reading

Latest Drug News

Is Fomepizole the Key to Overcoming Antibiotic-Resistant Pneumonia?
The new drug target sheds insights into strategies to fight drug-resistant S. pneumoniae, stated research.
 Combination Therapy Benefits Septic Shock Patients
The effectiveness of adding fludrocortisone to hydrocortisone vs hydrocortisone alone among patients with septic shock was analyzed using target trial emulation.
Are Painkillers Safe for Back Pain?
Safety and effectiveness of commonly used painkillers (analgesics) for short-term relief of low back pain remain uncertain.
 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

High Out of Pocket Cost of Medications to Treat Cardiovascular Diseases in India Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests